Halozyme Therapeutics Inc (NAS:HALO)
$ 48.13 0.1 (0.21%) Market Cap: 6.12 Bil Enterprise Value: 6.95 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 87/100

Halozyme Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 07:50PM GMT
Release Date Price: $15.92 (+0.13%)
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I am the SMid-Cap biotech analyst from Barclays.

It's my pleasure to introduce our next speaker Laurie Stelzer, Chief Financial Officer, from Halozyme.

Laurie D. Stelzer
Halozyme Therapeutics, Inc. - Senior VP & CFO

Thank you, Gena, and let me grab the clicker. Okay. Good afternoon, everyone. I am delighted to be here today to talk about Halozyme. Halozyme is a unique biotech company. We have a very unique strategy with a 2 pillar structure for growth. I'm going to talk about both those pillars but both pillars, both ENHANZE and PEGPH20 really will drive a great deal of shareholder value.

Before I get started, the forward-looking statements I'll be making today, I direct you to our SEC filings for a full list of risks and uncertainties.

So as I mentioned, we have 2 pillars for growth, 2 engines for growth in the future. On the left-hand side, you'll see our ENHANZE. This is a drug technology platform. In this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot